Susquehanna International Group’s Aegerion Pharmaceuticals AEGR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2016
Q4 | – | Sell |
-91,300
| Closed | -$271K | – | 10576 |
|
|
2016
Q3 | $271K | Hold |
91,300
| – | – | ﹤0.01% | 7100 |
|
|
2016
Q2 | $136K | Sell |
91,300
-7,800
| -8% | -$17.8K | ﹤0.01% | 7875 |
|
|
2016
Q1 | $367K | Sell |
99,100
-205,700
| -67% | -$1.27M | ﹤0.01% | 6924 |
|
|
2015
Q4 | $3.08M | Buy |
304,800
+82,100
| +37% | +$988K | ﹤0.01% | 3233 |
|
|
2015
Q3 | $3.03M | Sell |
222,700
-440,900
| -66% | -$7.85M | ﹤0.01% | 3482 |
|
|
2015
Q2 | $12.6M | Buy |
663,600
+434,100
| +189% | +$9.4M | 0.01% | 1740 |
|
|
2015
Q1 | $6.01M | Sell |
229,500
-137,000
| -37% | -$3.49M | ﹤0.01% | 2487 |
|
|
2014
Q4 | $7.67M | Sell |
366,500
-91,200
| -20% | -$2.3M | ﹤0.01% | 2319 |
|
|
2014
Q3 | $15.3M | Buy |
457,700
+100,000
| +28% | +$3.1M | 0.01% | 1682 |
|
|
2014
Q2 | $11.5M | Sell |
357,700
-656,100
| -65% | -$24.4M | 0.01% | 1951 |
|
|
2014
Q1 | $46.8M | Buy |
1,013,800
+280,700
| +38% | +$16.5M | 0.02% | 664 |
|
|
2013
Q4 | $52M | Buy |
733,100
+338,100
| +86% | +$25.9M | 0.02% | 636 |
|
|
2013
Q3 | $33.9M | Sell |
395,000
-67,600
| -15% | -$5.73M | 0.02% | 829 |
|
|
2013
Q2 | $29.3M | Buy |
+462,600
| New | +$24.6M | 0.02% | 842 |
|
Susquehanna International Group's AEGR Position: Q4 2016 in Review
Susquehanna International Group sold out of Aegerion Pharmaceuticals (AEGR) in Q4 2016, closing a stake of 76,709 shares — an estimated $228K sold.
Susquehanna International Group first reported a position in AEGR in Q2 2013 and held it in 13 quarters. The position peaked at $19.3M in Q3 2013. 0 funds tracked by Wall St. Rank hold AEGR as of Q4 2016.
- Susquehanna International Group reported no remaining Aegerion Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
- Susquehanna International Group sold 76,709 Aegerion Pharmaceuticals shares in Q4 2016, an estimated $228K.
- Susquehanna International Group first reported a position in Aegerion Pharmaceuticals in Q2 2013 and held it in 13 quarters.
- Susquehanna International Group's Aegerion Pharmaceuticals position peaked at $19.3M in Q3 2013.
- 0 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q4 2016.
Based on Susquehanna International Group's 13F filing for Q4 2016, filed 14 Feb 2017.